Searched for
DRUGMAKER CIPLA
Cipla appoints health chief Shivam Puri to lead One India businessCipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take...- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Cipla USA recalls Nilotinib anti-cancer capsules over manufacturing issue: USFDACipla USA is recalling over 400 cartons of its generic anti-cancer drug Nilotinib Capsules (150 mg and 200 mg) due to a manufacturing issue...
- US unit of India's Cipla recalls six batches of bronchospasm inhalerIndian pharmaceutical company Cipla has recalled six batches of its Albuterol Sulfate HFA Inhalation Aerosol in the US due to a container d...
- India's demand for COVID-19 drug remdesivir to fall, says CiplaCipla was among the first companies in India to launch a generic version of remdesivir, developed by U.S.-based Gilead Sciences, and as of ...
- InvaGen, Exelan acquisition will give Cipla manufacturing plant, R&D base in USCipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...
- Cipla surges on US acquisitions worth $550 millionCipla shares climbed over 3% in morning trade after the company said its UK-based subsidiary, Cipla EU, will acquire two US-based companies.
- Cipla asks government to revoke five patents held by NovartisCipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...
- Cipla puts Medpro buyout on hold over valuation issuesCipla decides to put on hold its $220-million acquisition plan of the third-largest South African drugmaker Cipla Medpro due to valuation i...
- Cipla set to buy 51% of S Africa's Cipla Medpro for about $220 millionCipla said on Wednesday it will buy 51% of Cipla Medpro for about $220 million, valuing the beleaguered South African company at about $440...
- Cipla’s patent win against Roche boosts hopes of generic drugmakersThe Delhi HC ruling favouring India’s second largest drugmaker Cipla has come as a shot in the arm for other generic makers who are fightin...
- Cipla hits 52-week high on robust Q1 earnings; domestic sales reboundCipla surged over 6% in opening trade after it reported a 52% increase in net profit. UBS maintains a 'buy’ on the stock with a target pric...
- Bayer demands withdrawal of Natco Pharma's compulsory licenceIn March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original medicine's pr...
- Cipla down 3.7 pc; Q3 net lags forecastShares in drugmaker Cipla fell nearly 4 percent on Monday morning, after it reported a larger-than-expected 19.4 percent decline in third-q...
- Cipla makes cancer drug cheaperCipla has launched a copycat version of German pharma company Bayer’s cancer medicine Nexavar at one-tenth the price.
- Cipla in talks with global cos for research agreementMumbai-based drugmaker Cipla is in talks with global pharma majors for a drug research and supply agreement, said a top company executive o...
Load More
